SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron
Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs, today announced the appointment of
Kimberly Manhard to Heron's Board of
Directors.
"I am pleased to welcome Kimberly to the Heron Board," said
Barry Quart, Pharm.D., President and Chief Executive Officer of
Heron. "Kimberly has been a key member of our management team over
the last 4 years and has been instrumental in driving the drug
development and regulatory strategies for our pain and CINV
franchises. We look forward to Kimberly's contributions to our
Board."
Ms. Manhard has served as Executive Vice President, Drug
Development of Heron since 2016. Ms. Manhard has more than 25
years of experience in drug development, regulatory affairs and
pharmaceutical operations. From 2014 to 2016, Ms. Manhard served as
a director of Heron. From 2006 to 2016, she held various
positions at Ardea Biosciences, Inc., a wholly owned subsidiary of
AstraZeneca PLC, most recently serving as Senior Vice President of
Regulatory Affairs and Development Operations. In her role at
Ardea, Ms. Manhard was instrumental in the development and
2015 regulatory approval of Zurampic® (lesinurad) for
the treatment of hyperuricemia associated with gout. Previously,
Ms. Manhard was President of her own consultancy firm, and, in
2002, she served as Vice President of Regulatory Affairs at
Exelixis, Inc. Prior to Exelixis, Ms. Manhard held various
positions at Agouron Pharmaceuticals, Inc., a division of the
Warner-Lambert Company, supporting development and
commercialization of anticancer and antiviral products, including
Viracept® (nelfinavir). She also held various
positions at Bristol-Myers Squibb Company in regulatory affairs,
where she was responsible for oncology compounds, including
Taxol® (paclitaxel), and infectious disease compounds,
including Videx® (didanosine) and Zerit®
(stavudine). Ms. Manhard is a member of the Board of Trustees
for the Fleet Science Center. She received a B.S. degree in zoology
and a B.A. degree in French from the University of Florida.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs. Heron is developing novel,
patient-focused solutions that apply its innovative science and
technologies to already-approved pharmacological agents for
patients suffering from pain or cancer. For more information,
visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission. Forward looking statements
reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be
required by law.
Investor Relations and Media Contact:
David Szekeres
Senior VP, General Counsel, Business Development and Corporate
Secretary
Heron Therapeutics, Inc.
dszekeres@herontx.com
858-251-4447
View original
content:http://www.prnewswire.com/news-releases/heron-therapeutics-appoints-kimberly-manhard-to-board-of-directors-300928988.html
SOURCE Heron Therapeutics, Inc.